Product category:
Chromatographs: gas
News Release from: Agilent Technologies Europe | Subject: Can-BD
Edited by the Laboratorytalk Editorial
Team on 02 May 2008
Spray-drying technology for nucleic acid
APIs
Agilent Technologies has secured an exclusive license to Aktiv-Dry's Can-BD drying technology for nucleic acid active pharmaceutical ingredients (APIs)
Can-BD is a continuous drying technology that produces uniform particles of low moisture nucleic acids, under very mild conditions, in a fraction of the time required by current batch freeze-drying methods The closed nature of the drying and collection system also reduces the risk of product contamination
This article was originally published on Laboratorytalk on 15 Aug 2001 at 8.00am (UK)
Related stories
Discount on GC and GC/MS systems
Agilent Technologies Europe has announced a 15% discount on new gas chromatograph (GC) and gas chromatograph/mass selective (GC/MS) detection systems purchased before 16 December 2001
The new spray-drying technology is expected to significantly reduce capital requirements and labor costs associated with large-scale drying of therapeutic nucleic acids.
"Agilent has long recognised that nucleic acid drying methods present a significant barrier to economic production of nucleic acid therapeutics at commercial scale," said James Powell, general manager of Agilent's Nucleic Acid Solutions Division.
"We have been actively evaluating alternative technologies, and we are now confident that Aktiv-Dry's CAN-BD technology will significantly lower cost-of-goods for our customers while providing a higher-quality nucleic acid API." Agilent will present a poster on this technology entitled "Can-BD: a novel drying technology for therapeutic oligonucleotides" at the upcoming Tides Conference at Red Rock Resort and Spa in Las Vegas, USA, May 2008.
• Agilent Technologies Europe: contact details and other news
• Email this article to a colleague
• Register for the free Laboratorytalk email newsletter
• Laboratorytalk Home Page

